GPP
CYTK icon

Great Point Partners’s Cytokinetics CYTK Stock Holding History

Great Point Partners’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-253,000
Closed -$5.48M – 37
2020
Q3 		$5.48M Buy
+253,000
New +$5.92M 0.49% 31
2016
Q1 		– Sell
-106,800
Closed -$1.12M – 34
2015
Q4 		$1.12M Buy
+106,800
New +$1.05M 0.47% 23

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Great Point Partners's CYTK Position: Q4 2025 in Review

Great Point Partners sold out of Cytokinetics (CYTK) in Q4 2025, closing a stake of 150,000 shares — an estimated $8.24M sold.

Great Point Partners first reported a position in CYTK in Q1 2014 and held it in 23 quarters. The position peaked at $55.2M in Q3 2020. 430 funds tracked by Wall St. Rank hold CYTK as of Q4 2025.

  • Great Point Partners reported no remaining Cytokinetics position as of Q4 2025 after selling out during the quarter.
  • Great Point Partners sold 150,000 Cytokinetics shares in Q4 2025, an estimated $8.24M.
  • Great Point Partners first reported a position in Cytokinetics in Q1 2014 and held it in 23 quarters.
  • Great Point Partners's Cytokinetics position peaked at $55.2M in Q3 2020.
  • 430 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2025.

Based on Great Point Partners's 13F filing for Q4 2025, filed 17 Feb 2026.